Reading CGEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CGEM free→Reading CGEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CGEM free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, while compared with sector peers, it is above typical. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $13.55. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.81x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.86 → $-0.85 (+0.9% / 30d). 4 raised, 0 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 100% of analysts rate Buy.
2 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$255.
How much price usually moves either way.
On a bad day, this stock has moved -$628.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,421.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: New data on CLN-978 could show its effectiveness. This may attract more investment.
Confirms:More positive clinical data from the Phase 1 OUTRACE trials will come next quarter.
Disproves:Negative clinical data or no new updates on CLN-978 in the next quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CGEM yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. CLN-978 On June 10, 2026, the Company shared updated clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA (“OUTRACE RA”) and in patients with treatment-refractory moderate to severe SLE (“OUTRACE SLE”). As of May 20, 2026, new multi-dose data in the Phase 1 OUTRACE RA clinical trial demonstrate the robust efficacy profile of CLN-978 observed in two heavily pre-treated, poly-refractory patients, including a DAS28-ESR remissio…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2023-Q3, 2024-Q1, 2024-Q2, 2024-Q3
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CGEM Cullinan Therapeutics, Inc. | Above typical Show detailsSector percentile: 91 of 100 | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to extend the company's cash resources to provide runway into 2029 based on its current operating plan.
The company is advancing its Phase 1 OUTRACE clinical trials for CLN-978 in treatment-refractory RA and SLE.
Why it matters: Extending cash runway is key for funding ongoing trials and operations. It impacts investor confidence.
Confirms:New funding or partnerships may extend cash runway into 2029.
Disproves:No news on cash runway extension or funding shortfalls.
Other Events. On June 6, 2026, the Company shared initial clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA ("OUTRACE RA") and in patients with treatment-refractory moderate to severe SLE ("OUTRACE SLE"). As of May 15, 2026, 29 patients had been evaluated across various dose levels in the OUTRACE SLE and RA clinical trials. SLE (n=18) RA (n=11) Dose levels investigated Safety PD* Efficacy Safety PD* Efficacy Cohort 1 (D1: 10 μg) 3 3 3…
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Other Events. On May 18, 2026, the Company announced initial clinical data from its Phase 1 OUTRACE Program for CLN-978 in patients with treatment-refractory RA and in patients with treatment-refractory moderate to severe SLE. As of a January 14, 2026 cutoff date, 14 patients were dosed across the RA (cohorts 1-3, n=5) and SLE (cohorts 1-3, n=9) clinical trials. All day 1 step up doses were 10 micrograms (“mcg”) and day 8 target doses were either 20 mcg (cohort 2) or 30 mcg (cohort 3). Follow…
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.